Microbiology Spectrum · 2022 · 10 citations · 16 references
MedicineInfectious DiseasesPreventive MedicineEarly DetectionImmunizationVaccinologyAdult ImmunizationDiagnostic Test EvaluationInfectious Disease ScreeningRapid Diagnostic TestsVaccinationVaccine-preventable DiseasesDengue FeverDengue VaccinesHigh-sensitivity AssaysRapid Screening Tests
Dengue remains a significant public health issue, with over 5.2 million cases reported to the World Health Organization (WHO) in 2019. The tetravalent dengue vaccine (CYD-TDV) is currently licensed for use in those aged ≥9 years; however, vaccinees with no previous exposure to dengue experience an increased risk of hospitalized and severe dengue upon subsequent heterotypic infection. Consequently, WHO recommends screening for prior dengue infection before vaccination. Screening tests for previous infection need to be highly specific and sensitive, and deliverable at the point-of-care. High sensitivity ensures that the largest number of individuals with previous infection can be identified and vaccinated, while high specificity prevents the inadvertent vaccination of those without previous infection. This study of the OnSite Dengue IgG Rapid Test, which was explicitly developed to meet this need, found that it had both high specificity (98.0% [95% CI = 95.9 to 99.2]) and sensitivity (95.3% [95% CI = 91.7 to 97.6]).
16
Antibody-dependent enhancement of severe dengue disease in humans
Leah C. Katzelnick, Lionel Gresh, M. Elizabeth Halloran et al. · Science · 2017 · 1.2K citations · Full text
Maria Rosario Capeding, Ngoc Huu Tran, Sri Rezeki Hadinegoro et al. · The Lancet · 2014 · 969 citations
Zika virus infection enhances future risk of severe dengue disease
Leah C. Katzelnick, César Narvaez, Sonia Arguello et al. · Science · 2020 · 279 citations · Full text